Khiron Life Sciences has announced that it has entered into an agreement with a prominent Colombian research hospital to explore the potential of medical cannabis to support treatment of dermatological conditions.
Centro Dermatologico Federico Lleras Acosta (CDFLLA) will support Khiron in performing studies on the cosmetics and cosmeceutical products it manufactures as well as studying the potential of the ingredient as a supportive therapy for skin conditions.
“A growing number of healthcare professionals believe that medical cannabis provides significant benefits for patients suffering from a range of dermatological conditions,” said Dr Claudia Rojas, Director of CDFLLA. “Khiron and CDFLLA are committed to developing a body of scientific research that supports these findings in order to help patients manage their skin conditions and aid doctors in making informed healthcare decisions.”
Dr Edwin Bendek, Khiron Medical Director, Skincare, added, “Khiron is proud to work closely with the Centro Dermatológico Federico Lleras Acosta (CDFLLA) to pioneer cannabis research in Latin America. With the launch of our Kuida brand, the first CBD-based cosmeceutical brand in Latin America, combined with our partnership with CDFLLA, we are closer to achieving our mission of bringing safe and medically-validated medical cannabis products to market.”